Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ProOxy · 1 trial · 1 indication
Upon acceptance,pictures are taken and acne lesions are identified and counted and after 4,8, and 12 weeks during and after application of ProOxy.
| Arm | Type | Description |
|---|---|---|
| ProOxy, Effects and Side Effects in treating acne | EXPERIMENTAL | Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months. |
| Name | Type | Description |
|---|---|---|
| ProOxy | DRUG | Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime. |
Inclusion Criteria: * patients with acne on their faces only * patients who are at least 18 years of age * patients who have normal and disease free skin at the dorsal surface of the upper arm. * patients who are willing to follow instructions on both the Patch Test Part one and Part Two procedures...
ProOxy is an investigational small molecule being developed for the treatment of acne vulgaris. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its effects and side effects in patients with acne.
ProOxy is being developed by ICU Medical, Inc., a company traded on the NASDAQ under the ticker symbol ICUI. The company is conducting clinical research on this investigational drug for the treatment of acne vulgaris.
ProOxy is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and the drug remains in early-stage clinical development for acne vulgaris.
ProOxy has one completed clinical trial, identified as NCT01682200, titled "Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of Acne." This Phase 1 study enrolled 50 participants with acne vulgaris and was conducted in the Philippines.
ProOxy is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being studied under the name ProOxy in clinical trials for the treatment of acne vulgaris.